TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...
TARRYTOWN, N.Y., Oct. 21, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA® ...
Credit: Getty Images. The approval was based on data from the phase 3 BUTTERFLEYE and FIREFLEYE trials. The Food and Drug Administration (FDA) has approved Eylea ® (aflibercept) for the treatment of ...
Eylea (aflibercept) injections can cause both mild and serious side effects, though serious side effects are rare according to clinical trials. Mild side effects include eye floaters, redness, and ...
Credit: Getty Images. The sBLA is supported by data from the phase 3 PANORAMA trial and the NIH-sponsored Protocol W trial. The Food and Drug Administration (FDA) has accepted for review the ...
P041, an aflibercept biosimilar, showed noninferiority to originator aflibercept (Eylea) in maintaining vision in nAMD patients over 52 weeks. The study involved 168 patients, with 145 completing the ...
Please provide your email address to receive an email when new articles are posted on . Investigators retrospectively analyzed visual and anatomic outcomes of patients who were attempted to be weaned ...
LONG BEACH, Calif. -- Prefilled syringes to treat macular degeneration caused larger and more frequent spikes in intraocular pressure (IOP) as compared with medication drawn from vials, a study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results